These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 17540778)

  • 1. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties.
    Laugel B; van den Berg HA; Gostick E; Cole DK; Wooldridge L; Boulter J; Milicic A; Price DA; Sewell AK
    J Biol Chem; 2007 Aug; 282(33):23799-810. PubMed ID: 17540778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs.
    Wooldridge L; Clement M; Lissina A; Edwards ES; Ladell K; Ekeruche J; Hewitt RE; Laugel B; Gostick E; Cole DK; Debets R; Berrevoets C; Miles JJ; Burrows SR; Price DA; Sewell AK
    J Immunol; 2010 Apr; 184(7):3357-66. PubMed ID: 20190139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities.
    Hutchinson SL; Wooldridge L; Tafuro S; Laugel B; Glick M; Boulter JM; Jakobsen BK; Price DA; Sewell AK
    J Biol Chem; 2003 Jul; 278(27):24285-93. PubMed ID: 12697765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface.
    Wooldridge L; Hutchinson SL; Choi EM; Lissina A; Jones E; Mirza F; Dunbar PR; Price DA; Cerundolo V; Sewell AK
    J Immunol; 2003 Dec; 171(12):6650-60. PubMed ID: 14662868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding.
    Cole DK; Dunn SM; Sami M; Boulter JM; Jakobsen BK; Sewell AK
    Mol Immunol; 2008 May; 45(9):2700-9. PubMed ID: 18243322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers.
    Wooldridge L; Scriba TJ; Milicic A; Laugel B; Gostick E; Price DA; Phillips RE; Sewell AK
    Eur J Immunol; 2006 Jul; 36(7):1847-55. PubMed ID: 16783852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-affinity CD8 variants enhance the sensitivity of pMHCI antigen recognition via low-affinity TCRs.
    Knezevic L; Wachsmann TLA; Francis O; Dockree T; Bridgeman JS; Wouters A; de Wet B; Cole DK; Clement M; McLaren JE; Gostick E; Ladell K; Llewellyn-Lacey S; Price DA; van den Berg HA; Tabi Z; Sessions RB; Heemskerk MHM; Wooldridge L
    J Biol Chem; 2023 Aug; 299(8):104981. PubMed ID: 37390984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coreceptor CD8-driven modulation of T cell antigen receptor specificity.
    van den Berg HA; Wooldridge L; Laugel B; Sewell AK
    J Theor Biol; 2007 Nov; 249(2):395-408. PubMed ID: 17869274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers.
    Melenhorst JJ; Scheinberg P; Chattopadhyay PK; Lissina A; Gostick E; Cole DK; Wooldridge L; van den Berg HA; Bornstein E; Hensel NF; Douek DC; Roederer M; Sewell AK; Barrett AJ; Price DA
    J Immunol Methods; 2008 Sep; 338(1-2):31-9. PubMed ID: 18675271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glu227-->Lys substitution in the acidic loop of major histocompatibility complex class I alpha 3 domain distinguishes low avidity CD8 coreceptor and avidity-enhanced CD8 accessory functions.
    Shen L; Potter TA; Kane KP
    J Exp Med; 1996 Nov; 184(5):1671-83. PubMed ID: 8920857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface.
    Wooldridge L; van den Berg HA; Glick M; Gostick E; Laugel B; Hutchinson SL; Milicic A; Brenchley JM; Douek DC; Price DA; Sewell AK
    J Biol Chem; 2005 Jul; 280(30):27491-501. PubMed ID: 15837791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain.
    Purbhoo MA; Boulter JM; Price DA; Vuidepot AL; Hourigan CS; Dunbar PR; Olson K; Dawson SJ; Phillips RE; Jakobsen BK; Bell JI; Sewell AK
    J Biol Chem; 2001 Aug; 276(35):32786-92. PubMed ID: 11438524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region.
    Wooldridge L; Lissina A; Vernazza J; Gostick E; Laugel B; Hutchinson SL; Mirza F; Dunbar PR; Boulter JM; Glick M; Cerundolo V; van den Berg HA; Price DA; Sewell AK
    Eur J Immunol; 2007 May; 37(5):1323-33. PubMed ID: 17429845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8 coreceptor-mediated focusing can reorder the agonist hierarchy of peptide ligands recognized via the T cell receptor.
    Clement M; Knezevic L; Dockree T; McLaren JE; Ladell K; Miners KL; Llewellyn-Lacey S; Rubina A; Francis O; Cole DK; Sewell AK; Bridgeman JS; Price DA; van den Berg HA; Wooldridge L
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34272276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity thresholds for naive CD8+ CTL activation by peptides and engineered influenza A viruses.
    Denton AE; Wesselingh R; Gras S; Guillonneau C; Olson MR; Mintern JD; Zeng W; Jackson DC; Rossjohn J; Hodgkin PD; Doherty PC; Turner SJ
    J Immunol; 2011 Dec; 187(11):5733-44. PubMed ID: 22039305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cells.
    Laugel B; Cole DK; Clement M; Wooldridge L; Price DA; Sewell AK
    J Leukoc Biol; 2011 Dec; 90(6):1089-99. PubMed ID: 21954283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8
    Dockree T; Holland CJ; Clement M; Ladell K; McLaren JE; van den Berg HA; Gostick E; L Miners K; Llewellyn-Lacey S; Bridgeman JS; Man S; Bailey M; Burrows SR; Price DA; Wooldridge L
    Immunol Cell Biol; 2017 Jan; 95(1):68-76. PubMed ID: 27670790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement.
    Kerry SE; Buslepp J; Cramer LA; Maile R; Hensley LL; Nielsen AI; Kavathas P; Vilen BJ; Collins EJ; Frelinger JA
    J Immunol; 2003 Nov; 171(9):4493-503. PubMed ID: 14568922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coreceptor affinity for MHC defines peptide specificity requirements for TCR interaction with coagonist peptide-MHC.
    Hoerter JA; Brzostek J; Artyomov MN; Abel SM; Casas J; Rybakin V; Ampudia J; Lotz C; Connolly JM; Chakraborty AK; Gould KG; Gascoigne NR
    J Exp Med; 2013 Aug; 210(9):1807-21. PubMed ID: 23940257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CD8 in aberrant function of cytotoxic T lymphocytes.
    Kessler B; Hudrisier D; Cerottini JC; Luescher IF
    J Exp Med; 1997 Dec; 186(12):2033-8. PubMed ID: 9396772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.